Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Wyniki testu 6-minutowego chodu u chorych na mukowiscydozę kwalifikowanych do przeszczepienia płuc / The results of the 6-minute walking test in patients with cystic fibrosis during acceptation process for lung transplantation

100%
Prusak J., Tomalak W., Leżański A., Pogorzelski A.
Advances in Rehabilitation
|
2014
|
vol. 28
|
issue 3
21-27
EN
Introduction: Lung transplantation in patients with cystic fibrosis is a robust therapeutic option to treat patients with cystic fibrosis. The aim of the study was to estimate of exercise tolerance using 6-minute walking test in patients with cystic fibrosis during the acceptation process for lung transplantation. Material and methods: This study included 49 CF patients (27 female, 22 male). The mean age was 24,6 ± 9,4 years in range from 9 to 45 years. 47 patients finished 6-minute walking test and were included in the statistical analysis. Results: Mean distance in 6-minute walking test was 493,4 ± 101,0 meters. At rest SaO2 was 90,1 ± 4,9% and was 74,5 ± 10,5% post-test. The values of FEV1 was 0,71 ± 0,2 4 (22,1 % pred.), FVC was 1,34 ± 0,54 (35,7 % pred.). Values of FVC, FEV1 and pre-test SaO2 and HR was a little correlated with the distance of the test. Conclusions: The 6-minute walking test is a useful tool in the assessment when to list patients for lung transplantation
2
Content available remote

Cystic fibrosis is a risk factor for celiac disease

64%
Walkowiak J., Blask-Osipa A., Lisowska A., Oralewska B., Pogorzelski A., Cichy W., Sapiejka E., Kowalska M., Korzon M., Szaflarska-Popławska A.
|
2010
|
vol. 57
|
issue 1
115-118
EN
Background: The coexistence of cystic fibrosis (CF) and celiac disease (CD) has been reported. To our knowledge there is no study directly comparing the incidence of CD in CF patients to that in the general population at the same time. There is no published data on genetic predisposition to CD in CF patients either. Therefore, in the present study we aimed to assess the genetic predisposition to CD and its incidence in CF patients comparing it to data from the general population. Patients and methods: Two hundred eighty-two CF patients were enrolled in the study. In 230 CF patients the genetic predisposition to CD (the presence of HLA-DQ2/ DQ8) was assessed. In all CF patients, serological screening for CD was conducted. In patients with positive antiendomysial antibodies (EMA) gastroduenoscopy was offered. Intestinal histology was classified according to modified Marsh criteria. The results of serological CD screening in 3235 Polish schoolchildren and HLA-DQ typing in 200 healthy subjects (HS) were used for comparison. Results: Positive EMA was found in 2.84% of the studied CF patients. The incidence of proven CD was 2.13%. The incidence of CD as well as positive serological screening were significantly more frequent in the CF group than in the general population. The frequency of CD-related HLA-DQ alleles in CF and HS did not differ. Conclusions: Genetic predisposition to celiac disease in cystic fibrosis patients is similar to that of the general population. However, our results suggest that cystic fibrosis is a risk factor for celiac disease development.
3
Content available remote

Antibiotic therapy and fat digestion and absorption in cystic fibrosis

64%
Lisowska A., Pogorzelski A., Oracz G., Skorupa W., Cofta S., Szydłowski J., Socha J., Walkowiak J.
|
2011
|
vol. 58
|
issue 3
345-347
EN
Antibiotic therapy in the cystic fibrosis (CF) mouse model has been shown to result in reduced bacterial load of the intestine and significant body mass gain. The effect was suggested to be linked to the improvement of intestinal digestion and absorption. Therefore, we aimed to assess the influence of routinely applied antibiotic therapy in CF patients on fat assimilation. Twenty-four CF patients aged 6 to 30 years entered the study. Inclusion criteria comprised confirmed exocrine pancreatic insufficiency and bronchopulmonary exacerbation demanding antibiotic therapy. Exclusion criteria comprised: antibiotic therapy six weeks prior to the test, liver cirrhosis, diabetes mellitus, oxygen dependency, the use of systemic corticosteroids. In all enrolled CF subjects, 13C-labelled mixed triglyceride breath test (13C MTG-BT) was performed to assess lipid digestion and absorption, before and after antibiotic therapy. Sixteen subjects were treated intravenously with ceftazidime and amikacin, eight patients orally with ciprofloxacin. Cumulative percentage dose recovery (CPDR) was considered to reflect digestion and absorption of lipids. The values are expressed as means (medians). The values of CPDR before and after antibiotic therapy did not differ in the whole studied group [4.6(3.3) % vs. 5.7(5.3) %, p = 0.100] as well as in the subgroup receiving them intravenously [4.6(3.2) % vs. 5.7(5.3) %, p = 0.327] or in that with oral drug administration [4.6(3.4) % vs. 5.7(5.4) %, p = 0.167]. In conclusion, antibiotic therapy applied routinely in the course of pulmonary exacerbation in CF patients does not seem to result in an improvement of fat digestion and absorption.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.